Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers
Journal of Clinical Oncology, 10/29/09
Graeser MK et al. –The goal of this study was to estimate the risk for contralateral breast cancer in members of BRCA1- and BRCA2-positive families and to determine predictive risk factors. Contralateral breast cancer risk depends on age at first breast cancer and on the affected BRCA gene, and this risk should be considered in treatment planning.
Methods- Retrospective, multicenter, cohort study
- 2,020 women with unilateral breast cancer from 978 families who had BRCA1 or BRCA2 mutation
- Cox regression analysis applied to assess association of age at first breast cancer with time from first to contralateral breast cancer, stratified by affected BRCA gene
- Cumulative risk for contralateral breast cancer 25 years after first breast cancer 47.4% (95% CI, 38.8% to 56.0%) for patients from families with BRCA1 or BRCA2 mutations
- Members of families with BRCA1 mutations had 1.6-fold (95% CI, 1.2-fold to 2.3-fold) higher risk of contralateral breast cancer than members of families with BRCA2 mutations
- Members of families with BRCA1 mutations had 1.6-fold higher risk of contralateral breast cancer than members of families with BRCA2 mutations
- Younger age at first breast cancer associated with significantly higher risk of contralateral breast cancer in patients with BRCA1 mutation
- trend was observed in patients with BRCA2 mutation
- After 25 years, 62.9% (95% CI, 50.4% to 75.4%) of patients with BRCA1 mutation who were younger than 40 years of age at first breast cancer developed contralateral breast cancer, compared with only 19.6% (95% CI, 5.3% to 33.9%) of those older than 50 years of age at first breast cancer
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
Clinical Cancer Research, 12/11/09
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma
Clinical Cancer Research, 12/11/09
Platelets release novel thiol isomerase enzymes which are recruited to the cell surface following activation
British Journal of Haematology, 12/11/09
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatocyte Nuclear Factor-4–Independent Synthesis of Coagulation Factor VII in Breast Cancer Cells and Its Inhibition by Targeting Selective Histone Acetyltransferases
Molecular Cancer Research, 12/11/09
Tamoxifen Inhibits TRPV6 Activity via Estrogen Receptor–Independent Pathways in TRPV6-Expressing MCF-7 Breast Cancer Cells
Molecular Cancer Research, 12/11/09
Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients
Cancer Immunology, Immunotherapy, 12/11/09
Article Search
Sponsor


See Latest Articles


